Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.830
-0.100 (-5.18%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Cellectis Revenue
Cellectis had revenue of $9.50M in the quarter ending June 30, 2024, with 374.91% growth. This brings the company's revenue in the last twelve months to $19.64M, down -20.70% year-over-year. In the year 2023, Cellectis had annual revenue of $9.19M, down -64.26%.
Revenue (ttm)
$19.64M
Revenue Growth
-20.70%
P/S Ratio
n/a
Revenue / Employee
$88,846
Employees
221
Market Cap
188.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Adaptimmune Therapeutics | 141.46M |
| NeuroPace | 71.82M |
| Semler Scientific | 61.74M |
| Electromed | 54.72M |
| MediWound | 20.14M |
| Vaxart | 13.93M |
| Atai Life Sciences | 378.00K |
CLLS News
- 8 days ago - Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - GlobeNewsWire
- 2 months ago - Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety - GlobeNewsWire
- 2 months ago - Cellectis: Cheap With Promising But Speculative Cancer Therapies - Seeking Alpha
- 2 months ago - Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors - GlobeNewsWire
- 3 months ago - Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer - GlobeNewsWire
- 3 months ago - Cellectis Provides Financial Results for the Second Quarter 2024 - GlobeNewsWire
- 3 months ago - FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment - GlobeNewsWire
- 3 months ago - FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment - GlobeNewsWire